[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
January 5, 2000

Global Action Against Multidrug-Resistant Tuberculosis—Reply

Author Affiliations
 

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorMargaret A.WinkerMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor

JAMA. 2000;283(1):54-55. doi:10-1001/pubs.JAMA-ISSN-0098-7484-283-1-jbk0500

In Reply: In response to Dr Schraufnagel and Abubaker, we would first emphasize that MDRTB, defined as resistance to at least isoniazid and rifampin, is not synonymous with drug-resistant TB. MDRTB can persist and even increase in areas that use the currently recommended treatment protocol, DOTS.

Approximately 15 years of short-course chemotherapy in the setting of a national program produced impressive declines in the overall prevalence of drug-resistant TB in Korea.1 The prevalence of MDRTB, however, was 1.7% in 1980 and 5.3% in 1995.1 The rifampin-based short-course treatment regimens remain reasonably effective for drug-resistant TB that is susceptible to rifampin and other first-line agents.1 These regimens are ineffective treatments for MDRTB.2 Because standard short-course treatments are ineffective, one national TB referral hospital in Korea changed to individualized regimens based on drug sensitivity testing to treat patients with MDRTB.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×